DE

470.26

-1.59%↓

FDX

245.41

+1.56%↑

PAYX

155.09

+0.39%↑

CPRT

57.56

+0.61%↑

HEICA

212.9

+0.18%↑

DE

470.26

-1.59%↓

FDX

245.41

+1.56%↑

PAYX

155.09

+0.39%↑

CPRT

57.56

+0.61%↑

HEICA

212.9

+0.18%↑

DE

470.26

-1.59%↓

FDX

245.41

+1.56%↑

PAYX

155.09

+0.39%↑

CPRT

57.56

+0.61%↑

HEICA

212.9

+0.18%↑

DE

470.26

-1.59%↓

FDX

245.41

+1.56%↑

PAYX

155.09

+0.39%↑

CPRT

57.56

+0.61%↑

HEICA

212.9

+0.18%↑

DE

470.26

-1.59%↓

FDX

245.41

+1.56%↑

PAYX

155.09

+0.39%↑

CPRT

57.56

+0.61%↑

HEICA

212.9

+0.18%↑

Ocugen Inc

Затворен

0.68 6.25

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.62

Максимум

0.7

Ключови измерители

By Trading Economics

Приходи

-910K

-14M

Продажби

-372K

764K

EPS

-0.05

Марж на печалбата

-1,816.754

Служители

95

EBITDA

-603K

-13M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+926.15% upside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

57M

233M

Предишно отваряне

-5.57

Предишно затваряне

0.68

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

Ocugen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.04.2024 г., 14:32 ч. UTC

Значими двигатели на пазара

Ocugen Gets FDA Clearance for IND Amendment for OCU400

Сравнение с други в отрасъла

Ценова промяна

Ocugen Inc Прогноза

Ценова цел

By TipRanks

926.15% нагоре

12-месечна прогноза

Среден 6.67 USD  926.15%

Висок 8 USD

Нисък 4 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocugen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

3 ratings

3

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

0.6351 / 0.7995Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.